PDL BioPharma, Inc.
PDL BIOPHARMA, INC. (Form: 8-K, Received: 03/21/2017 06:02:12)


 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 21, 2017

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware
 
94-3023969
(State or Other Jurisdiction of Incorporation)
 
(I.R.S. Employer Identification No.)


932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

¨      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 








Item 7.01 Other Events.
 
On March 21, 2017, PDL BioPharma, Inc. (the Company) will make presentations and participate in conferences with investors and analysts in connection with the Oppenheimer 27 th Annual Healthcare Conference in New York City. A copy of the Company’s presentation materials has been posted to the Company’s website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business are disclosed in the “Risk Factors” contained in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2017. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
 
Description
 
 
 
99.1
 
Presentation






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)
 
 
 
By:
 
/s/ John P. McLaughlin
 
 
John P. McLaughlin
 
 
President and Chief Executive Officer




Dated: March 21, 2017






Exhibit Index


Exhibit No.
 
Description
99.1
 
Presentation





Exhibit 99.1

SLIDE1A39.JPG





SLIDE2A39.JPG





SLIDE3A39.JPG





SLIDE4A39.JPG





SLIDE5A39.JPG





SLIDE6A39.JPG





SLIDE7A39.JPG





SLIDE8A37.JPG





SLIDE9A35.JPG





SLIDJ98.JPG





SLIDJ99.JPG





SLIDK01.JPG





SLIDK02.JPG





SLIDK03.JPG





SLIDK04.JPG





SLIDK05.JPG





SLIDK06.JPG





SLIDK07.JPG





SLIDK08.JPG





SLIDK09.JPG





SLIDK10.JPG





SLIDK11.JPG





SLIDK12.JPG





SLIDK13.JPG





SLIDK14.JPG





SLIDK15.JPG





SLIDK16.JPG





SLIDK17.JPG





SLIDK18.JPG





SLIDK19.JPG





SLIDK20.JPG





SLIDK21.JPG





SLIDK22.JPG





SLIDK23.JPG





SLIDK24.JPG





SLIDK25.JPG





SLIDK26.JPG





SLIDK27.JPG





SLIDK28.JPG





SLIDK29.JPG





SLIDK30.JPG





SLIDK31.JPG





SLIDK32.JPG





SLIDK33.JPG





SLIDK34.JPG





SLIDK35.JPG





SLIDK36.JPG





SLIDK37.JPG





SLIDK38.JPG





SLIDK39.JPG